Secukinumab in moderate to severe hidradenitis suppurativa: Week 16 results of hurley stage II and III from the sunshine and sunrise phase 3 randomized trials

被引：0

作者：

Kimball, Alexa B. ^{[1
,2
]}

Alavi, Afsaneh ^{[3
,4
]}

Jemec, Gregor B. E. ^{[3
,5
]}

Zouboulis, Christos C. ^{[3
,6
,7
,8
,9
,10
]}

Wozniak, Magdalena B. ^{[11
]}

Uhlmann, Lorenz ^{[12
]}

Llobet-Martinez, Angela ^{[12
]}

Ravichandran, Shoba ^{[13
]}

Marzano, Angelo V. ^{[3
,14
,15
]}

Reguiai, Ziad ^{[3
,16
]}

机构：

[1] Harvard Med Sch, Boston, MA USA

[2] Beth Israel Deaconess Med Ctr, Dermatol, Boston, MA USA

[3] European Hidradenitis Suppurat Fdn eV, Dessau, Germany

[4] Mayo Clin, Dermatol, Rochester, MN USA

[5] Zealand Univ Hosp Roskilde, Dermatol, Roskilde, Denmark

[6] Brandenburg Med Sch Theodor Fontane, Dessau, Germany

[7] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Dermatol, Dessau, Germany

[8] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Venereol, Dessau, Germany

[9] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Allergol, Dessau, Germany

[10] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Immunol, Dessau, Germany

[11] Novartis Ireland Ltd, Dublin, Ireland

[12] Novartis Pharma AG, Basel, Switzerland

[13] Novartis Pharmaceut, E Hanover, NJ USA

[14] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[15] Univ Milan, Dermatol Pathophysiol & Transplantat, Milan, Italy

[16] Polyclin Courlancy Bezannes, Dermatol, Reims, France

来源：

EXPERIMENTAL DERMATOLOGY | 2023年 / 32卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：25 / 26

页数：2

共 50 条

[21] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized Phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB159 - AB159
[22] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide A.
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan D.
Pierce, Evangeline
Elmaraghy, Hany
Pillai, Sreekumar
Dawson, Zach
Chen, Sherry
Armengol, Clara
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
[23] Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study
Nina Magnolo
Külli Kingo
Vivian Laquer
John Browning
Adam Reich
Jacek C. Szepietowski
Deborah Keefe
Philemon Papanastasiou
Weibin Bao
Pascal Forrer
Manmath Patekar
Pediatric Drugs, 2022, 24 : 377 - 387
[24] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[25] Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study
Magnolo, Nina
Kingo, Kulli
Laquer, Vivian
Browning, John
Reich, Adam
Szepietowski, Jacek C.
Keefe, Deborah
Papanastasiou, Philemon
Bao, Weibin
Forrer, Pascal
Patekar, Manmath
PEDIATRIC DRUGS, 2022, 24 (04) : 377 - 387
[26] Efficacy and safety of Adalimumab in patients with moderate to severe hidradenitis suppurativa: results from PIONEER II, a phase 3 randomised placebo-controlled trial
Herra, L. Escudero
Jemec, G. B. E.
Gottlieb, A.
Forman, S.
Giamarellos-Bourboulis, E. J.
Reguiai, Z.
Gu, Y.
Okun, M. M.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 34 - 35
[27] Bimekizumab efficacy and impact on pain in moderate-to-severe hidradenitis suppurativa: results from BE HEARD I and II
Ingram, John R.
Orenstein, Lauren A., V
Shi, Vivian Y.
Lev-Tov, Hadar
Prens, Errol
Lambert, Jeremy
Rolleri, Robert
Kirby, Brian
Rashidghamat, Ellie
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I53 - I53
[28] Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: Results from the placebo-controlled portion of a phase II, randomized, double-blind study
Kimball, A.
Jemec, G.
Okun, M.
Gu, Y.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB155 - AB155
[29] Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: results from the placebo-controlled portion of a phase II, randomized, double-blind study
Kimball, A. B.
Jemec, G.
Gu, Y.
Okun, M.
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 : 6 - 6
[30] Secukinumab is efficacious in clearing moderate-to-severe scalp psoriasis: 12 week results of a randomized phase IIIb study
Mate, E.
Bagel, J.
Callis-Duffin, K.
Moore, A.
Ferris, L.
Siu, K.
Guana, A.
Kianifard, F.
Nyirady, J.
Lebwohl, M.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 71 - 71

← 1 2 3 4 5 →